NuuChem Diagnostics Limited is a diagnostics company focusing on niche or orphan diagnostic test products, that although important, are often too limited in scope or too specialized for large mainstream corporate attention. The company works very closely with Catachem Incorporated in the USA, to bring some of Catachem's unique human diagnostic products to markets outside of the USA. NuuChem Diagnostics Limited is Catachem's Authorized Representative in the European Union. NuuChem's technical resources, when combined with those of Catachem Inc., allow it to provide solutions to various testing dilemmas facing diagnosticians in today's clinical laboratory.
In the case of NuuChem's initial product offering of enzymatic ethylene glycol , the products offers an alternative to sending samples to a third party laboratory for analysis using Gas Chromatography/Mass Spectroscopy (GC/MS) methodologies. Accurate results are obtained in minutes using the Catachem tests which are conducted in the laboratory's own facility using its own in-house clinical chemistry analyzer or in the case of the FasTox version a simple spectrophotometer. Fast results allow patients to be quickly triaged and treated with the goal of preventing serious damage before this has time to occur.
In a less time-critical situation, Catachem's Plasma Free Haemoglobin test, when run on a chemistry analyzer, can provide precise quantitative values for low levels of Haemoglobin in plasma to determine the degree of damage that a variety of blood manipulating protocols may be doing to red blood cells. This test product, when used on any clinical chemistry analyzer, is accurate to 2 mg/dL (1.20 mol/L).
Nuuchem will focus on various diverse and often overlooked testing needs, with a goal to provide value to the medical community and the patients that it serves.
In the case of NuuChem's initial product offering of enzymatic ethylene glycol , the products offers an alternative to sending samples to a third party laboratory for analysis using Gas Chromatography/Mass Spectroscopy (GC/MS) methodologies. Accurate results are obtained in minutes using the Catachem tests which are conducted in the laboratory's own facility using its own in-house clinical chemistry analyzer or in the case of the FasTox version a simple spectrophotometer. Fast results allow patients to be quickly triaged and treated with the goal of preventing serious damage before this has time to occur.
In a less time-critical situation, Catachem's Plasma Free Haemoglobin test, when run on a chemistry analyzer, can provide precise quantitative values for low levels of Haemoglobin in plasma to determine the degree of damage that a variety of blood manipulating protocols may be doing to red blood cells. This test product, when used on any clinical chemistry analyzer, is accurate to 2 mg/dL (1.20 mol/L).
Nuuchem will focus on various diverse and often overlooked testing needs, with a goal to provide value to the medical community and the patients that it serves.
Key Personnel
Dr. David James
David is an experienced, practicing Chemical Pathologist based in the UK, with more than 25 years of clinical background in diagnostic laboratories both within acute NHS hospitals and as Vice-President of a multi-national contract laboratory. After graduating from the Medical School in Cardiff, Wales having also obtained a first class Honors degree in Biochemistry, David's post graduate training at the University Hospital of Wales in Cardiff and at the University Children's Hospital in Munich lead to his specialist registration and an MD on the metabolism of Vitamin A and E in Cystic Fibrosis. David is a past chair of the National Quality Assessment Advisory Panel for Chemical Pathology which is part of an oversight mechanism of laboratory EQA programmes within the UK. He is currently part of the Joint Working Group, a body comprised of the chairs of the other advisory panels. David, in his role with NuuChem Diagnostics Limited, brings a breadth of understanding of the challenges facing the diagnostic communty and insights into what NuuChem and its partner Catachem can do to assist the practising diagnostician.
Catachem, Inc.
Based in Oxford, CT in the USA, Catachem, Inc. was founded in 1984, and has a long history of producing IVD reagents, including many with FDA 510k approval for use in human laboratories in the USA. Key personnel are:
Luis P. Leon
Luis started his career with Technicon Instruments, the original pioneering company in automated clinical chemistry testing. Luis helped develop many of the chemistries now in everyday use by the majority of clinical chemistry reagent manufacturers. Luis is Catachem's C.E.O. and Chief Scientist.
David M. Templeton
David joined Catachem in 2010, after a career with Genzyme Corporation and then Diagnostic Chemicals Limited (now Sekisui Diagnostics) where he founded the US arm of the organization and was the company's C.E.O. David is Catachem's President and Chief Operating Officer.
Janet Hassell
Janet joined Catachem in 2011 from Boehringer Ingelheim where she was a Research Associate and Quality Administrator. Janet ran the Technical Services Department at Diagnostic Chemicals Limited in the USA before joining Boehringer Ingelheim. Janet is a Senior Scientist at Catachem and also runs its Quality Assurance activities.
Scientific Advisory Committee
Dr. David Bush, Ph.D, Kent, England
David has had a long career in the Diagnostics Industry in Europe. After completing his Ph.D in Biochemistry at the University of Bath, David joined Whatman Biochemicals Limited in Maidstone, where he was in charge of Biochemistry research. He subsequently moved into the positions of Sales and Marketing Manager and after Genzyme's purchase of the company, he continued with Genzyme in the roles of Sales and Marketing Director, then Vice President of Sales & Marketing. David retired from Genzyme as Senior Vice President and General Manager of Genzyme Diagnostics (UK) and the title of Chairman of Genzyme Ltd. David has also performed the duties of Magistrate in Kent for a number of years and brings a pragmatism, as well as both product and market development expertise to NuuChem Diagnostics Limited.
Dr. John Reddington, Ph.D, DVM, Denver, CO
John is the President and CEO of the Morris Animal Foundation in Denver, CO, a non-profit organization that invests in science to advance animal health. John obtained his Ph.D as well as his Doctor of Veterinary Medicine degree from Washington State University in Pullman, WA. After running Biotherapeutics Inc., a diagnostics laboratory affiliated to Yale University that prepared biological materials for autologous immunotherapy, John founded DiagXotics Inc., the first company dedicated to the detection of diseases in the aquaculture industry. He was COO of Cambridge Biomedical Incorporated in Boston, MA, a clinical research organization, before taking his position at the Morris Animal Foundation. John has extensive experience in both human and veterinary diagnostics encompassing both assay development and product manufacture and brings this, along with a strong research background, to NuuChem Diagnostics Limited.
David is an experienced, practicing Chemical Pathologist based in the UK, with more than 25 years of clinical background in diagnostic laboratories both within acute NHS hospitals and as Vice-President of a multi-national contract laboratory. After graduating from the Medical School in Cardiff, Wales having also obtained a first class Honors degree in Biochemistry, David's post graduate training at the University Hospital of Wales in Cardiff and at the University Children's Hospital in Munich lead to his specialist registration and an MD on the metabolism of Vitamin A and E in Cystic Fibrosis. David is a past chair of the National Quality Assessment Advisory Panel for Chemical Pathology which is part of an oversight mechanism of laboratory EQA programmes within the UK. He is currently part of the Joint Working Group, a body comprised of the chairs of the other advisory panels. David, in his role with NuuChem Diagnostics Limited, brings a breadth of understanding of the challenges facing the diagnostic communty and insights into what NuuChem and its partner Catachem can do to assist the practising diagnostician.
Catachem, Inc.
Based in Oxford, CT in the USA, Catachem, Inc. was founded in 1984, and has a long history of producing IVD reagents, including many with FDA 510k approval for use in human laboratories in the USA. Key personnel are:
Luis P. Leon
Luis started his career with Technicon Instruments, the original pioneering company in automated clinical chemistry testing. Luis helped develop many of the chemistries now in everyday use by the majority of clinical chemistry reagent manufacturers. Luis is Catachem's C.E.O. and Chief Scientist.
David M. Templeton
David joined Catachem in 2010, after a career with Genzyme Corporation and then Diagnostic Chemicals Limited (now Sekisui Diagnostics) where he founded the US arm of the organization and was the company's C.E.O. David is Catachem's President and Chief Operating Officer.
Janet Hassell
Janet joined Catachem in 2011 from Boehringer Ingelheim where she was a Research Associate and Quality Administrator. Janet ran the Technical Services Department at Diagnostic Chemicals Limited in the USA before joining Boehringer Ingelheim. Janet is a Senior Scientist at Catachem and also runs its Quality Assurance activities.
Scientific Advisory Committee
Dr. David Bush, Ph.D, Kent, England
David has had a long career in the Diagnostics Industry in Europe. After completing his Ph.D in Biochemistry at the University of Bath, David joined Whatman Biochemicals Limited in Maidstone, where he was in charge of Biochemistry research. He subsequently moved into the positions of Sales and Marketing Manager and after Genzyme's purchase of the company, he continued with Genzyme in the roles of Sales and Marketing Director, then Vice President of Sales & Marketing. David retired from Genzyme as Senior Vice President and General Manager of Genzyme Diagnostics (UK) and the title of Chairman of Genzyme Ltd. David has also performed the duties of Magistrate in Kent for a number of years and brings a pragmatism, as well as both product and market development expertise to NuuChem Diagnostics Limited.
Dr. John Reddington, Ph.D, DVM, Denver, CO
John is the President and CEO of the Morris Animal Foundation in Denver, CO, a non-profit organization that invests in science to advance animal health. John obtained his Ph.D as well as his Doctor of Veterinary Medicine degree from Washington State University in Pullman, WA. After running Biotherapeutics Inc., a diagnostics laboratory affiliated to Yale University that prepared biological materials for autologous immunotherapy, John founded DiagXotics Inc., the first company dedicated to the detection of diseases in the aquaculture industry. He was COO of Cambridge Biomedical Incorporated in Boston, MA, a clinical research organization, before taking his position at the Morris Animal Foundation. John has extensive experience in both human and veterinary diagnostics encompassing both assay development and product manufacture and brings this, along with a strong research background, to NuuChem Diagnostics Limited.